S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Alkermes plc Reports Second Quarter 2014 Financial Results|
|Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis|
|Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder|
|Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain|
|Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic|
|Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia|
|Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results|
|Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference|
|ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib|
|ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer|
Click above to view more mutual fund data and stats for alks - Alkermes PLC.